Abstract:How rapid HIV infection progresses to AIDS and to death is affected by different factors. This study explores survival times and associated survival factors from treatment initiation to death or censoring in antiretroviral therapy-experienced HIV-seropositive adults in Malawi from 2004-2015. A multicentre non-concurrent, retrospective cohort study was undertaken from eight ART Centres where patients’ medical records (PMRs) of HIV-positive adult patients aged 15+ years were reviewed. A life table, the Kaplan-Meier log-rank, and Cox Proportion Hazard regression were used to calculate survival time-to-death and its correlates, respectively. Hazard ratio with 95%CI and p<0.05 were used to declare statistical significance. Data for (n=9,953) patients were abstracted from PMRs. Patients median age was 40 (IQR: 33-48 years). 60.8% were females, 45.2% were aged 20-39 years, and 78.8% were married. At treatment initiation, 48.1% had advanced HIV disease clinical stage III, 24.5% had WHO stage IV, whereas 27.5% were asymptomatic – of which, 24.9% and 2.6% initiated ART due to low CD4+ count and PMTCT’s Option-B+ eligibility criteria, respectively. Survival function findings revealed that each patient had a single entry into the study. Exit time ranged from 1 to 9,224 days with the mean value of 2,421.9 days, occurring at the rate of 0.00004883 event-failure per-person-day. Time-to-death was observed at the rate of 1.78/100 person-years-at-risk (PYAR). 213 deaths (18.1%) occurred early in year-one post-ART-initiation. Deaths occurred more among persons of 20-39 years (N=470, 39.97%), and of 40-54 years (N=483, 41.07%), and was mostly due to mycobacterial pathogenic conditions (N=106, 37.3%) in particular TB infection (N=103); most of which were PTB cases (N=69, 66.9%). Mortality was high in Southern region (63.1%, N=743) but was least in Northern region (N=313) [ 0.0001]. In a multivariate Cox regression predictive model, males gender (aHR=1.42), patients age-groups of 20-39 years (aHR=1.63), 40-54 years (aHR=1.71), and 55+ years (aHR=2.66), Mzuzu Central hospital ART centre (aHR=2.66), Thyolo District hospital ART centre (aHR=3.02), semi-rural areas (aHR=1.30), urban areas (aHR=0.80), being single (aHR=0.86), chronic cough and/or breathlessness (aHR=1.19), chronic diarrhoea or weight loss (aHR=1.43), chronic fever and/or severe headache (aHR=1.30), skin or oral lesion (aHR=1.33), WHO clinical stage III (aHR=17.90), WHO clinical stage IV (aHR=20.09), low baseline CD4 count <250 cells/µL, (aHR=1.17), high baseline VL>1,000 copies/mL (aHR=2.46), Nevirapine-based therapies (aHR=1.14), and HIV duration of 3-5 years (aHR=1.17), 6-10 years (aHR=1.19) and >10 years (aHR=1.16) were all statistically significantly associated with time-to-death. This study has demonstrated survival factors associated with time-to-death among HIV-positive adults in Malawi. In order to effectively reduce AIDS mortality and win the war against AIDS-related death, the need to critically address and carefully prioritise the identified factors in HIV/AIDS management is great and cannot be overemphasised.

Mortality Among Children Under Five Years of Age Living With HIV on Antiretroviral Treatment From HIV Case Surveillance Data, Malawi, 2022

High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countries

Mortality and its predictors among human immunodeficiency virus-infected children younger than 15 years receiving antiretroviral therapy in Ethiopia: a systematic review and meta-analysis

Mortality of children and adolescents co-infected with tuberculosis and HIV: a systematic review and meta-analysis

Hospital admission and its common causes in children on antiretroviral therapy (ART) in Lilongwe Malawi between 2001 and 2016: a retrospective cross-sectional study

Understanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings

The global epidemiology of adolescents living with HIV: time for more granular data to improve adolescent health outcomes

Long‐term risk of mortality and loss to follow‐up in children and adolescents on antiretroviral therapy in Asia

Characteristics of HIV-infected children seen in Western Kenya

Predicting mortality within 1 year of ART initiation in children and adolescents living with HIV in sub-Saharan Africa: a retrospective observational cohort study

Analysis of Time-to-Death Survival Function in a Nationally Representative Random Sample of HIV-seropositive Treatment-experienced Adult Patients from Malawi – A Historical Cohort Sample of 2004-2015 HIV Data

Trends in COVID-19 admissions and deaths among people living with HIV in South Africa: analysis of national surveillance data

Trends in continuity of treatment among children and adolescents living with HIV in 14 districts in South Africa from 2018-2023: A retrospective program analysis

Impact of HIV exposure without infection on hospital course and mortality among young children in sub-Saharan Africa: a multi-site cohort study

Treatment Outcomes of HIV Infected Children after Initiation of Antiretroviral Therapy in Southwest China: an Observational Cohort Study

Mortality Rate in a Cohort of People Living With HIV in Rural Tanzania After Accounting for Unseen Deaths Among Those Lost to Follow-up

24-Month HIV-free survival among HIV-exposed Infants in Lesotho: the PEAWIL cohort study

Human Immunodeficiency Virus (HIV) Drug Resistance in African Infants and Young Children Newly Diagnosed With HIV: A Multicountry Analysis

Changes in early HIV/AIDS mortality rates in people initiating antiretroviral treatment between 2013 and 2023: A 10-year multicenter survival study in Senegal

Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies

Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries